Physician profile
Paul Schmidt
NPI 1245252444
$8,998.47
in general payments reported to CMS, 2019-2025
63 companies · $2,763 in 2025
The $2,763 reported for 2025 was more than what 78% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $657 · 2021: $799 · 2022: $963 · 2023: $1,899 · 2024: $1,917 · 2025: $2,763.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,516 · Education: $63.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,516.00 |
| Education | $63.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,145.22 | 2021-2025 | Qulipta, Ubrelvy |
| Pfizer INC. | $890.95 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $590.31 | 2019-2025 | |
| Ucb, INC. | $505.85 | 2019-2025 | Briviact, Rystiggo, Fintepla |
| Takeda Pharmaceuticals U.S.A., INC. | $465.95 | 2023-2025 | Hyqvia, Gammagard |
| Protega Pharmaceutials INC | $291.04 | 2025 | Roxybond |
| Emd Serono, INC. | $259.00 | 2022-2025 | Mavenclad |
| Biogen, INC. | $239.49 | 2019-2025 | Vumerity, Tysabri |
| Scilex Pharmaceuticals INC. | $227.39 | 2021-2024 | Ztlido |
| Otsuka America Pharmaceutical, INC. | $184.13 | 2023-2025 | Rexulti, Nuedexta |
| Lilly USA, LLC | $178.61 | 2019-2024 | Emgality, Reyvow, Amyvid |
| Genzyme Corporation | $172.60 | 2019-2023 | |
| Eisai INC. | $168.79 | 2019-2024 | |
| Harmony Biosciences LLC | $157.27 | 2022-2023 | Wakix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $141.95 | 2023-2025 | Relistor |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Schmidt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.